About Merck Serono
Merck Serono is the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, a
global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland,
Merck Serono discovers, develops, manufactures and markets prescription medicines
of both chemical and biological origin in specialist indications. In the United
States and Canada, EMD Serono operates as a separately incorporated affiliate of
Merck Serono.
Merck Serono has leading brands serving patients with cancer (Erbitux®, cetuximab),
multiple sclerosis (Rebif®, interferon beta-1a), infertility (Gonal-f®, follitropin
alfa), endocrine and metabolic disorders (Saizen® and Serostim®, somatropin), (Kuvan®,
sapropterin dihydrochloride), (Egrifta™, tesamorelin), as well as cardiometabolic
diseases (Glucophage®, metformin), (Concor®, bisoprolol), (Euthyrox®, levothyroxine).
Not all products are available in all markets.
With an annual R & D expenditure of over € 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in rheumatology.
|
Visual and video library
Download a comprehensive range of visuals and videos.
Click hereThe KRAS Test
Get more information about the KRAS test procedure in this video.
Click hereErbitux - Mode of Action
Get more information about Erbitux mode of action in this new video.
Click here |